Danaher Raises 2026 EPS Guidance to $8.35–$8.55 and Plans Masimo Acquisition
Danaher reported Q1 2026 revenue of $6.0 billion, up 3.5% year-over-year, and non-GAAP EPS of $2.06, a 9.5% increase driven by Bioprocessing and Life Sciences strength. The company raised full-year adjusted EPS guidance to $8.35–$8.55 and announced plans to acquire Masimo to expand its patient monitoring portfolio.
1. Q1 2026 Financial Results
Danaher delivered first quarter 2026 revenue of $6.0 billion, up 3.5% year-over-year, with non-GAAP adjusted EPS rising 9.5% to $2.06. Operating cash flow reached $1.3 billion, supported by robust Bioprocessing sales and stronger-than-expected Life Sciences performance offsetting a subdued respiratory season at Cepheid.
2. Full-Year Guidance Revision
The company raised its full-year 2026 adjusted diluted EPS outlook to a range of $8.35 to $8.55, up from $8.35 to $8.50, and reiterated expectations for core revenue growth of 3% to 6%. This adjustment reflects confidence in sustained top-line momentum and margin expansion across key segments.
3. Masimo Acquisition Intent
Danaher announced its intention to acquire Masimo, a provider of pulse oximetry and patient monitoring solutions, aiming to leverage the Danaher Business System to integrate Masimo’s technology and global scale. The deal targets enhanced performance and expanded market reach within critical care and patient monitoring markets.